Kenvue (NYSE:KVUE) Sets New 52-Week High - Time to Buy?

Kenvue Inc. (NYSE:KVUE - Get Free Report) shares reached a new 52-week high on Monday . The stock traded as high as $23.76 and last traded at $23.75, with a volume of 332500 shares. The stock had previously closed at $23.68.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on KVUE shares. Bank of America boosted their target price on shares of Kenvue from $24.00 to $27.00 and gave the stock a "buy" rating in a research report on Tuesday, October 22nd. UBS Group boosted their price objective on shares of Kenvue from $20.00 to $22.00 and gave the company a "neutral" rating in a research report on Wednesday, August 7th. Jefferies Financial Group assumed coverage on shares of Kenvue in a research report on Tuesday, September 24th. They set a "buy" rating and a $27.00 price objective for the company. Royal Bank of Canada downgraded shares of Kenvue from an "outperform" rating to a "sector perform" rating and set a $24.00 price objective for the company. in a research report on Tuesday, September 24th. Finally, Piper Sandler boosted their price objective on shares of Kenvue from $20.00 to $21.00 and gave the company a "neutral" rating in a research report on Monday, September 23rd. One analyst has rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $22.64.

Kenvue Price Performance

The company has a current ratio of 0.99, a quick ratio of 0.68 and a debt-to-equity ratio of 0.69. The business's fifty day moving average is $22.65 and its 200 day moving average is $20.55. The firm has a market capitalization of $45.54 billion, a P/E ratio of 43.27, a P/E/G ratio of 3.10 and a beta of 1.36.

Kenvue (NYSE:KVUE - Get Free Report) last released its earnings results on Thursday, November 7th. The company reported $0.28 EPS for the quarter, topping analysts' consensus estimates of $0.27 by $0.01. Kenvue had a net margin of 6.88% and a return on equity of 21.41%. The business had revenue of $3.90 billion for the quarter, compared to the consensus estimate of $3.92 billion. During the same period in the previous year, the firm earned $0.31 EPS. The business's revenue for the quarter was down .4% on a year-over-year basis. As a group, analysts forecast that Kenvue Inc. will post 1.07 EPS for the current year.

Kenvue Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, November 27th. Stockholders of record on Wednesday, November 13th will be issued a dividend of $0.205 per share. The ex-dividend date of this dividend is Wednesday, November 13th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.45%. Kenvue's dividend payout ratio is currently 149.09%.

Institutional Investors Weigh In On Kenvue

A number of large investors have recently made changes to their positions in the company. Riverview Trust Co acquired a new position in Kenvue in the 3rd quarter valued at approximately $30,000. Ashton Thomas Securities LLC acquired a new position in Kenvue in the 3rd quarter valued at approximately $35,000. Deseret Mutual Benefit Administrators increased its stake in Kenvue by 49.7% in the 3rd quarter. Deseret Mutual Benefit Administrators now owns 1,960 shares of the company's stock valued at $45,000 after buying an additional 651 shares during the period. Studio Investment Management LLC increased its stake in Kenvue by 52.1% in the 2nd quarter. Studio Investment Management LLC now owns 2,468 shares of the company's stock valued at $45,000 after buying an additional 845 shares during the period. Finally, AlphaMark Advisors LLC acquired a new position in Kenvue in the 3rd quarter valued at approximately $77,000. Institutional investors and hedge funds own 97.64% of the company's stock.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.